Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Bemarituzumab by Amgen for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase I for Squamous Non-Small Cell Lung Cancer. According to...
Xgeva by Amgen for Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis): Likelihood of Approval
Xgeva is under clinical development by Amgen and currently in Phase II for Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell...
Romosozumab by Amgen for Osteogenesis Imperfecta: Likelihood of Approval
Romosozumab is under clinical development by Amgen and currently in Phase I for Osteogenesis Imperfecta. According to GlobalData, Phase I...
Tezepelumab by Amgen for Chronic Urticaria Or Hives: Likelihood of Approval
Tezepelumab is under clinical development by Amgen and currently in Phase II for Chronic Urticaria Or Hives. According to GlobalData,...
Avacopan by Amgen for Systemic Lupus Erythematosus: Likelihood of Approval
Avacopan is under clinical development by Amgen and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase...
Aflibercept biosimilar by Amgen for Macular Edema: Likelihood of Approval
Aflibercept biosimilar is under clinical development by Amgen and currently in Pre-Registration for Macular Edema. According to GlobalData, Pre-Registration drugs...
Aflibercept biosimilar by Amgen for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval
Aflibercept biosimilar is under clinical development by Amgen and currently in Pre-Registration for Wet (Neovascular / Exudative) Macular Degeneration. According...
Latikafusp by Amgen for Solid Tumor: Likelihood of Approval
Latikafusp is under clinical development by Amgen and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Zeluvalimab by Amgen for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic...
Zeluvalimab by Amgen for Malignant Mesothelioma: Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Malignant Mesothelioma. According to GlobalData, Phase I...
Zeluvalimab by Amgen for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. According to...
Apremilast by Amgen for Bullous Pemphigoid: Likelihood of Approval
Apremilast is under clinical development by Amgen and currently in Phase II for Bullous Pemphigoid. According to GlobalData, Phase II...
Erenumab by Amgen for Pain: Likelihood of Approval
Erenumab is under clinical development by Amgen and currently in Phase II for Pain. According to GlobalData, Phase II drugs...
Zeluvalimab by Amgen for Small-Cell Lung Cancer: Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase...
Zeluvalimab by Amgen for Ovarian Cancer: Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I...
Rozibafusp alfa by Amgen for Systemic Lupus Erythematosus: Likelihood of Approval
Rozibafusp alfa is under clinical development by Amgen and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData,...
AMG-119 by Amgen for Small-Cell Lung Cancer: Likelihood of Approval
AMG-119 is under clinical development by Amgen and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Amgen's Aflibercept Biosimilar?
Aflibercept Biosimilar is a fusion protein commercialized by Amgen, with a leading Pre-Registration program in Macular Edema. According to Globaldata,...
Tezepelumab by Amgen for Churg-Strauss Syndrome: Likelihood of Approval
Tezepelumab is under clinical development by Amgen and currently in Phase II for Churg-Strauss Syndrome. According to GlobalData, Phase II...
Blinatumomab by Amgen for Follicular Lymphoma: Likelihood of Approval
Blinatumomab is under clinical development by Amgen and currently in Phase III for Follicular Lymphoma. According to GlobalData, Phase III...